AP2261A - Process and methods for the preparation of optically active CIS-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3-oxathiolane or pharmaceutically acceptable saltsthereof. - Google Patents

Process and methods for the preparation of optically active CIS-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3-oxathiolane or pharmaceutically acceptable saltsthereof.

Info

Publication number
AP2261A
AP2261A AP2007004147A AP2007004147A AP2261A AP 2261 A AP2261 A AP 2261A AP 2007004147 A AP2007004147 A AP 2007004147A AP 2007004147 A AP2007004147 A AP 2007004147A AP 2261 A AP2261 A AP 2261A
Authority
AP
ARIPO
Prior art keywords
cytosin
oxathiolane
hydroxymethyl
preparation
methods
Prior art date
Application number
AP2007004147A
Other languages
English (en)
Other versions
AP2007004147A0 (en
Inventor
Ioana Simion
Alex Cimpoia
Original Assignee
Shire Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Canada Inc filed Critical Shire Canada Inc
Publication of AP2007004147A0 publication Critical patent/AP2007004147A0/xx
Application granted granted Critical
Publication of AP2261A publication Critical patent/AP2261A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
AP2007004147A 2005-03-14 2005-03-14 Process and methods for the preparation of optically active CIS-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3-oxathiolane or pharmaceutically acceptable saltsthereof. AP2261A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2005/000384 WO2006096954A1 (en) 2005-03-14 2005-03-14 Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1´-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof

Publications (2)

Publication Number Publication Date
AP2007004147A0 AP2007004147A0 (en) 2007-10-31
AP2261A true AP2261A (en) 2011-07-26

Family

ID=36991222

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004147A AP2261A (en) 2005-03-14 2005-03-14 Process and methods for the preparation of optically active CIS-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3-oxathiolane or pharmaceutically acceptable saltsthereof.

Country Status (15)

Country Link
EP (1) EP1866303B1 (es)
JP (1) JP5001254B2 (es)
KR (1) KR100993031B1 (es)
CN (1) CN101142211B (es)
AP (1) AP2261A (es)
AU (1) AU2005329355B8 (es)
BR (1) BRPI0520041A2 (es)
CA (1) CA2599825C (es)
ES (1) ES2446102T3 (es)
IL (1) IL185370A0 (es)
MX (1) MX2007011274A (es)
NI (1) NI200700235A (es)
NO (1) NO338553B1 (es)
NZ (1) NZ560972A (es)
WO (1) WO2006096954A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110257396A1 (en) * 2006-10-30 2011-10-20 Lupin Limited Process for the manufacture of cis(-)-lamivudine
IN2015DN02599A (es) 2007-09-28 2015-09-18 Avexa Ltd
EP2358708B1 (en) * 2008-12-08 2013-06-12 Hetero Research Foundation Optical resolution of substituted 1.3-oxathiolane nucleosides
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
JP2012136526A (ja) * 2012-02-09 2012-07-19 Shire Canada Inc 光学的に活性なｃｉｓ−２−ヒドロキシメチル−４−（シトシン−１’−イル）−１，３−オキサチオランまたはその薬学的に許容される塩の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2095613A1 (en) * 1990-11-13 1992-05-14 Bernard Belleau Substituted 1, 3-oxathiolanes and substituted 1, 3-dithiolanes with antiviral properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
US6600044B2 (en) * 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2095613A1 (en) * 1990-11-13 1992-05-14 Bernard Belleau Substituted 1, 3-oxathiolanes and substituted 1, 3-dithiolanes with antiviral properties

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BELLEAU B. ET AL. BIOORG. MED. CHEM. LET. vol. 3, no. 8, August 1993, pages 1723 - 1728 *
WANG W. ET AL. TETRAHEDRON LETTERS vol. 35, no. 27, 04 July 1994, pages 4739 - 4742 *

Also Published As

Publication number Publication date
AU2005329355B2 (en) 2011-08-18
CN101142211B (zh) 2013-06-05
AU2005329355A1 (en) 2006-09-21
NO20075224L (no) 2007-10-11
NZ560972A (en) 2009-07-31
KR20080008322A (ko) 2008-01-23
MX2007011274A (es) 2008-03-13
WO2006096954A1 (en) 2006-09-21
EP1866303A1 (en) 2007-12-19
ES2446102T3 (es) 2014-03-06
EP1866303B1 (en) 2013-11-27
KR100993031B1 (ko) 2010-11-08
CA2599825A1 (en) 2006-09-21
AP2007004147A0 (en) 2007-10-31
IL185370A0 (en) 2008-02-09
CA2599825C (en) 2012-06-19
EP1866303A4 (en) 2010-05-19
NI200700235A (es) 2012-05-23
AU2005329355B8 (en) 2012-02-23
NO338553B1 (no) 2016-09-05
JP2008533056A (ja) 2008-08-21
JP5001254B2 (ja) 2012-08-15
CN101142211A (zh) 2008-03-12
BRPI0520041A2 (pt) 2009-04-14

Similar Documents

Publication Publication Date Title
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
ZA200702382B (en) Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
HUE037069T2 (hu) Eljárás nagy tisztaságú 2,4'-metiléndifenildiizocianát elõállítására
EP1865967A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
IL176420A0 (en) Process for the manufacture of 2,3-dichloropyridine
IL178334A0 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
IL176872A0 (en) Amide derivatives, process for the preparation thereof and use thereof as an insecticide
IL185353A0 (en) Azabicycloalkane derivatives , pharmaceutical compositions containing the same and methods for the preparation thereof
EP1770085A4 (en) DIAMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND FUNGICIDE CONTAINING THE DERIVATIVE AS ACTIVE INGREDIENT
IL187235A0 (en) 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
WO2007016352A3 (en) Oral liquid losartan compositions
TNSN07317A1 (en) 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof
ZA200700397B (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
AP2261A (en) Process and methods for the preparation of optically active CIS-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3-oxathiolane or pharmaceutically acceptable saltsthereof.
EG25401A (en) Process for the preparation of urea.
USD582021S1 (en) Drop down hand rail
WO2007144699A3 (en) Process for the preparation of alfuzosin
WO2007007282A3 (en) Azabicyclo derivatives as muscarinic receptor antagonists
ZA200601001B (en) Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicament comprising the same
HK1100946A1 (en) 1-a-HALO-2,2-DIFLUORO-2-DEOXY-D-RIBOFURANOSE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF
ZA200707518B (en) Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3-Oxathiolane or pharmaceutically acceptable salts thereof
EP1781678A4 (en) 1 -? - HALOGEN-2,2-DIFLUOR-2-DESOXY-D-RIBOFURANOSEDERIVATE AND PROCESS FOR THE PRODUCTION THEREOF
USD539362S1 (en) Whimsical monkey spinner
IL186457A0 (en) Process for the preparation of 9,10-dehydro-12,13-desoxyepothilone derivatives
FR2892921B1 (fr) Injecteur d'implant ophtalmique.